Scott Tarriff, President and CEO at EAGLE PHARMACEUTICALS, INC. (EGRX), sold 14,050 shares at $87.85 ($1.2M) on 2015-12-01, disclosed to the SEC on 2015-12-02.
Scheduled sale ($1.2M) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $86.92 | 2,806 | $244K | 19.5% |
| 2 | $87.85 | 4,744 | $417K | 33.4% |
| 3 | $88.80 | 1,500 | $133K | 10.7% |
| 4 | $90.99 | 3,700 | $337K | 26.9% |
| 5 | $91.46 | 1,300 | $119K | 9.5% |
| Total | $88.93 avg | 14,050 |
| $1.2M |
| 100% |
| Filing → |
| EGRX | SELL | 2023-05-18 | $300K | — | Filing → |
| EGRX | SELL | 2023-05-15 | $1.2M | — | Filing → |
| EGRX | SELL | 2019-04-03 | $2.5M | — | Filing → |